Home
Resources
Product Analysis
Acknowledgements
About
Home
References
Industries
Industries
Medical
Products 21 to 29 of 29
Modify Display Properties
Biotech components
Business models
Country of production
Country of distribution
Intended consumer
Date added
Date last modified
Known funding amount
Funding types
Industry
Market status
Organization
Organization type(s)
Product categories
Production process
Source
Trading symbol
Value chain stage
Sort: Title (A-Z)
Date added (oldest-newest)
Date added (newest-oldest)
Date modified (oldest-newest)
Date modified (newest-oldest)
Title (A-Z)
Title (Z-A)
Organization (A-Z)
Organization (Z-A)
INXN-3004: AML
by
Intrexon
Biotech components:
Virus
Business models:
B2B
Country of production:
N/A
Country of distribution:
N/A
Intended consumer:
N/A
Date added:
2020/02/10 09:59 (5 years ago)
Date last modified:
2020/02/10 09:59 (5 years ago)
Known funding amount:
N/A
Funding types:
Shareholder Investment
Industry:
Medical
Market status:
Under Development
Organization type(s):
Public Company
Product categories:
Medical Treatment
Production process:
N/A
Source:
Web search
Trading symbol:
XON
(NASDAQ)
Value chain stage:
Finished Product
Mast-MO (antibiotic wasp venom)
by
University of Pennsylvania’s Perelman School of Medicine
Biotech components:
Animal
+
Bacteria
+
Molecule
Business models:
B2B
+
B2C
Country of production:
N/A
Country of distribution:
N/A
Intended consumer:
N/A
Date added:
2020/12/18 14:40 (4 years ago)
Date last modified:
2020/12/18 14:40 (4 years ago)
Known funding amount:
N/A
Funding types:
University
Industry:
Medical
Market status:
Early Stage Concept
Organization type(s):
University
Product categories:
Medical Treatment
Production process:
N/A
Source:
Web search
Trading symbol:
N/A
Value chain stage:
Input
MG53 (natural human protein) (preventing lethal lung damage from the flu)
by
Ohio State University
Biotech components:
Molecule
Business models:
B2C
Country of production:
N/A
Country of distribution:
N/A
Intended consumer:
N/A
Date added:
2020/12/18 14:39 (4 years ago)
Date last modified:
2020/12/18 14:39 (4 years ago)
Known funding amount:
N/A
Funding types:
University
Industry:
Medical
Market status:
Early Stage Concept
Organization type(s):
University
Product categories:
Medicine
+
Medical Treatment
Production process:
N/A
Source:
Web search
Trading symbol:
N/A
Value chain stage:
N/A
OG716: Lantibiotics
by
Oakbio
+
Oragenics
Biotech components:
Molecule
Business models:
B2C
Country of production:
N/A
Country of distribution:
N/A
Intended consumer:
N/A
Date added:
2019/09/12 15:12 (5 years ago)
Date last modified:
2019/09/12 15:16 (5 years ago)
Known funding amount:
N/A
Funding types:
Private Funding
+
Shareholder Investment
Industry:
Medical
Market status:
Early Stage Concept
Organization type(s):
Private Company
Product categories:
Medicine
Production process:
N/A
Source:
Web search
Trading symbol:
N/A
Value chain stage:
Finished Product
PRGN-3005: Cancer
by
Intrexon
Biotech components:
Gene Editing
+
Molecule
Business models:
B2B
Country of production:
N/A
Country of distribution:
N/A
Intended consumer:
N/A
Date added:
2019/09/12 14:31 (5 years ago)
Date last modified:
2019/09/12 14:31 (5 years ago)
Known funding amount:
N/A
Funding types:
Shareholder Investment
Industry:
Medical
Market status:
Under Development
Organization type(s):
Public Company
Product categories:
Medical Treatment
Production process:
N/A
Source:
Web search
Trading symbol:
XON
(NASDAQ)
Value chain stage:
Finished Product
PRGN-3006: AML and MDS
by
Intrexon
Biotech components:
Gene Editing
+
Molecule
Business models:
B2B
Country of production:
N/A
Country of distribution:
N/A
Intended consumer:
N/A
Date added:
2019/09/12 14:32 (5 years ago)
Date last modified:
2019/09/12 14:32 (5 years ago)
Known funding amount:
N/A
Funding types:
Shareholder Investment
Industry:
Medical
Market status:
Under Development
Organization type(s):
Public Company
Product categories:
Medical Treatment
Production process:
N/A
Source:
Web search
Trading symbol:
N/A
Value chain stage:
Finished Product
SNS-301 (noninfectious lambda bacteriophage viruses)
by
Sensei Biotherapeutics
Biotech components:
Virus
Business models:
B2C
Country of production:
N/A
Country of distribution:
N/A
Intended consumer:
N/A
Date added:
2020/12/18 14:40 (4 years ago)
Date last modified:
2020/12/18 14:40 (4 years ago)
Known funding amount:
28,500,000 USD
Funding types:
Private Funding
Industry:
Medical
Market status:
Under Development
Organization type(s):
Private Company
Product categories:
Medical Treatment
+
Medicine
Production process:
N/A
Source:
Web search
Trading symbol:
N/A
Value chain stage:
Input
Transgenic Strawberry Plants
by
Hokkai Sankyo Company Ltd
Biotech components:
Gene Editing
+
Plant
Business models:
B2B
Country of production:
N/A
Country of distribution:
N/A
Intended consumer:
N/A
Date added:
2020/01/21 15:00 (5 years ago)
Date last modified:
2020/01/21 15:00 (5 years ago)
Known funding amount:
N/A
Funding types:
Research Institution
Industry:
Medical
Market status:
On the market
Organization type(s):
Private Company
Product categories:
Medicine
Production process:
Open Release
Source:
Web search
Trading symbol:
N/A
Value chain stage:
Finished Product
Yeast based platform to synthesize complex bioactive molecules
by
Concordia University
Biotech components:
Yeast
Business models:
B2B
Country of production:
N/A
Country of distribution:
N/A
Intended consumer:
N/A
Date added:
2020/12/18 14:38 (4 years ago)
Date last modified:
2020/12/18 14:38 (4 years ago)
Known funding amount:
N/A
Funding types:
University
Industry:
Medical
+
Multipurpose
Market status:
Early Stage Concept
Organization type(s):
University
Product categories:
Medicine
+
Other
Production process:
N/A
Source:
Web search
Trading symbol:
N/A
Value chain stage:
Platform
1
2
3
Login
or
register
to add and edit products
Future
Bioengineered
Products
Home
Resources
Product Analysis
Acknowledgements
About
